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The frequency and implications of an elevated cardiac troponin (4th or 5th generation TnT) in
patients outside of the emergency department or presenting with non-cardiac conditions is
unclear.
Methods
Consecutive patients aged 18 years or older admitted for a primary non-cardiac condition
who had the 4th generation TnT drawn had the 5th generation TnT run on the residual blood
sample. Primary and secondary outcomes were all-cause mortality (ACM) and major
adverse cardiovascular events (MACE) respectively at 1 year.
Results
918 patients were included (mean age 59.8 years, 55% male) in the cohort. 69% had ele-
vated 5th generation TnT while 46% had elevated 4th generation TnT. 5th generation TnT
was more sensitive and less specific than 4th generation TnT in predicting both ACM and
MACE. The sensitivities for the 5th generation TnT assay were 85% for ACM and 90% for
MACE rates, compared to 65% and 70% respectively for the 4th generation assay. 5th gen-
eration TnT positive patients that were missed by 4th generation TnT had a higher risk of
ACM (27.5%) than patients with both assays negative (27.5% vs 11.1%, p<0.001), but lower
than patients who had both assay positive (42.1%). MACE rates were not better stratified
using the 5th generation TnT assay.
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Conclusions
In patients admitted for a non-cardiac condition, 5th generation TnT is more sensitive
although less specific in predicting MACE and ACM. 5th generation TnT identifies an inter-
mediate risk group for ACM previously missed with the 4th generation assay.
Introduction
Cardiac troponin is the recommended biomarker for the diagnosis of acute coronary syn-
drome (ACS), and its role in the rapid detection of ACS is well established [1, 2]. The transi-
tion from contemporary sensitivity to the high-sensitivity cardiac troponin has increased the
ability to reliably rule out patients for suspected ACS at the expense of specificity [2–5]. Conse-
quently, a large patient population has been identified with increased troponin values above
the 99th percentile who do not meet the 4th Universal Definition of Acute Myocardial Infarc-
tion [1]. Recent studies showed worse cardiovascular outcomes in undifferentiated emergency
department (ED) patients with elevated high sensitivity troponin values and both contempo-
rary sensitivity and high sensitivity troponin values are associated with outcomes in the ED
chest pain patients [6, 7]. More recent studies have tried to assess the implications of type 2
myocardial infarction, acute myocardial injury and chronic myocardial injury, but these are
often limited to patients with biomarkers drawn in the ED and include patients presenting
with a primary cardiac complaint (albeit non-ACS) [8–10]. However, considerably less is
known regarding the implication of increased troponin in patients hospitalized for non-ACS
conditions.
In a related note, cardiovascular risk is elevated in many non-cardiac conditions and tropo-
nin is known to be associated with all-cause mortality (ACM) in these non-ACS clinical popu-
lations [11–14]. A recent, large retrospective trial demonstrated that elevation in troponin is
associated with increased major adverse events in the absence of coronary artery disease, clini-
cal heart failure or renal dysfunction [12]. To date, no studies have directly compared contem-
porary and high sensitivity troponin values in hospitalized patients with a non-ACS
presentation. Many guideline documents recommend the routine assessment of troponin for
non-ACS presentation despite incompletely established risk associations and with a limited
understanding of the downstream implications [15–17]. This study aims to assess the predic-
tive nature of cardiac troponin while comparing different generations of troponin T assays.
Methods
Study population
This study included patients 18 years of age and older admitted to our quaternary care center
(University of Kentucky Medical Center) for a primary non-cardiac condition who had a con-
temporary sensitivity troponin assay ordered between January 2017 to October 2017. The clin-
ical laboratory identified patients based on the contemporary troponin assay being run from
all locations excluding our cardiovascular care units (CCU), primary cardiovascular floors,
Children’s Hospital, floors that housed adolescent or pediatric patients, and emergency depart-
ment. All patients had study procedures run on residual blood samples within 30 minutes after
it was deemed that there was no additional clinical need for the sample. All charts were subse-
quently reviewed for appropriateness of inclusion. Patients were excluded from the final analy-
sis if they were admitted to a primary cardiovascular service despite being on a traditionally
PLOS ONE 5th generation vs 4th generation troponin T in predicting outcomes in hospitalized patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0246332 February 9, 2021 2 / 11
Funding: The project described was supported by
the University of Kentucky Center for Health
Services Research Data, Analytics, and Statistical
Core. Roche Diagnostics provided the reagents for
the 5th generation Troponin T free of cost. No
additional renumeration was provided. The funders
had no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
Competing interests: The commercial funder,
Roche Diagnostics provided the reagents for the
5th generation Troponin T assay free of cost. No
additional renumeration was provided to any
authors. Roche Diagnostics was not involved in
study design, data collection, analysis, or
manuscript writing. This does not alter our
adherence to PLOS ONE policies on sharing data
and materials. Furthermore, there are no
competing interests with Roche Diagnostics or
other relevant entities for any of the authors with
regard to employment, consultancy, patents,
products in development, marketed products, etc.
non-cardiac service, presented with a primary cardiac complaint (chest pain or equivalent,
heart failure exacerbation, or arrhythmia) even if on a non-cardiac service, or presenting
within 7 days of a primary PCI or 30 days from an electrophysiologic or cardiothoracic
procedure.
The study was designed to be a matched comparison allowing for each study participant to
serve as their own control as they had both the high sensitivity and contemporary sensitivity
assay run. The comparison was to the predictive ability of each assay in predicting all-cause
mortality and CV events. Given there was no difference in event rates between the control and
study arm, a traditional sample size calculation was deferred. However, based on a previous
study of septic patients done at our institution, we anticipated a 30% all-cause mortality rate
and a 7% major adverse cardiovascular event rate in our study population with 3000 samples
requested (3 samples per participant and 1000 participants included in the study) [18].
The Institutional Review Board (IRB) approved the protocol and waived need for informed
consent given no patient contact was made by study personnel and the blood sample used for
study procedures was residual blood that would have otherwise been discarded. Roche Diag-
nostics provided the reagents prior to approval of the high sensitivity troponin assay by the
Food and Drug Administration as a part of an Investigator Initiated Research Agreeement.
Study procedures
All patients having a clinically indicated 4th generation Elecsys Troponin T immunoassay
(Roche Diagnostics, Germany) drawn reflexively had the 5th generation Elecsys Troponin T
immunoassay (Roche Diagnostics, Germany) run on the residual blood sample. Local valida-
tion and precision studies were done for both assays to identify 99th percentile cutoffs. For the
5th generation troponin T assay (5th generation TnT), gender specific cutoffs were used as per
the recommendations from Roche. Gender specific cutoffs were determined by running assays
on 300 healthy male and 300 healthy female volunteers. The 99th percentile from this norma-
tive data set was identified, and then compared to those reported in the literature. Abnormal
values for the 5th generation TnT assay were >13 ng/L for females and>18 ng/L for males.
Abnormal values for the 4th generation troponin T assay (4th generation TnT) were�0.01 ng/
mL. Troponins were deemed elevated if the peak value based on the assay specific cutoffs were
seen at any point in the hospitalization (not just index troponin). Given it was a new assay not
yet approved by the Food and Drug Administration, the 5th generation TnT was not reported
out clinically.
All clinical charts included were extensively reviewed to identify reason for admission, clin-
ical symptom or indication for troponin being drawn, ECG findings, clinical risk factors, and
additional cardiovascular testing results. ECG findings were reported based on the clinical
read of a board-certified cardiologist at the time care. A random sample of 100 charts were de-
identified and reviewed by a board-certified cardiologist (VG) to ensure consistency and accu-
racy of documentation.
Outcomes
The primary outcome for this study was all-cause mortality (ACM) at 1 year. The secondary
outcome was major adverse cardiovascular events (MACE) at 1 year. MACE included cardio-
vascular death, acute myocardial infarction (MI) or revascularization (PCI or CABG). Cardio-
vascular death was defined as fatal ventricular arrhythmia or cardiogenic shock as a primary or
significant secondary contributor (defined as mixed shock requiring inotropes and either sig-
nificant LV dysfunction or low mixed venous oxygen saturation). MI was defined using the
4th Universal Definition of Myocardial Infarction [1]. All outcomes were identified through
PLOS ONE 5th generation vs 4th generation troponin T in predicting outcomes in hospitalized patients
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review of the electronic health record. To minimize missing data, the Kentucky Health Infor-
mation Exchange was also accessed for potential admissions or testing at other participating
hospitals. The Kentucky Health Information Exchange is a consortium of over 1500 medical
centers, independent providers and pharmacies within the state to optimize data sharing. All
major cardiovascular events, including CV death were adjudicated by 2 board certified cardiol-
ogist who were blinded to their 5th generation TnT levels (JK and VG).
After directly comparing 4th generation versus 5th generation TnT, the cohort was then
divided into three groups: Group 1 was concordant negative (both 4th vs 5th generation TnT
negative), Group 2 was discordant (4th generation TnT negative, 5th generation TnT positive),
and Group 3 was concordant positive (both 4th and 5th generation TnT positive). This was to
identify the additive impact of the transition from the 4th generation to the 5th generation
assay in predicting ACM and MACE at 1 year. No patients had a positive 4th generation TnT
and a negative 5th generation TnT.
Statistical analysis
All categorical variables were reported in percentages and all continuous variables are reported
in means and standard deviations for normally distributed variables and medians and inter-
quartile ranges for non-normally distributed variables. Sensitivities, specificities and accuracies
were calculated for the 5th generation TnT assay and the 4th generation TnT assay for ACM
and MACE at 1 year. Then, receiver operator curves were generated for each test. Finally, the
ACM and MACE rates in the prespecified groups (concordant negative, discordant, and con-
cordant positive groups) were compared using Chi square analysis. SPSS v26 (IBM, Texas,
USA) was used for all analysis. A p value of<0.05 was used to assess statistical significance.
Results
Study population
A total of 927 were prospectively screened as having a 4th generation TnT ordered from the
inpatient, non-cardiovascular units. Nine patients were excluded due to a primary cardiovas-
cular reason for admission or admission to a cardiology service. No patients were excluded for
a recent cardiovascular procedure. A total of 918 patients were included in the final analysis
(S1 Fig). The mean age of the study population was 59.8 years with 45% female. This popula-
tion was noted to have significant cardiovascular risk factors, including hypertension (72%),
hyperlipidemia (52%), diabetes (24%), and known coronary artery disease (28%). Full baseline
demographic data is available in Table 1.
Patients primary reason for admission was also documented based on what was known at
the time of the troponin draw. Of the 918 patients included, the most common reason for
admission was acute respiratory failure (23.3%), acute or chronic stroke (23.3%), sepsis
(22.2%), hematology/oncology related illness (9.9%), trauma (7.6%), gastrointestinal bleeding
(6.0%), and pneumonia (5.7%). A non-cardiovascular operation was performed in 15.4% of
patients during that hospitalization prior to the troponin being drawn. Many patients had
multiple reasons for admission. Full breakdown of reason for admission is seen in Fig 1.
Clinical symptom triggering workup and ECG results
Clinical symptoms and indications that prompted ordering of the 4th generation TnT assay was
assessed (Table 2). Of the 918 patients, 43.9% had no reported cardiovascular symptoms that trig-
gered troponin collection. Of the remaining patients, 17.8% reported dyspnea while 17.7%
patients experienced preceding chest pain triggering ordering of troponin. Other cardiovascular
PLOS ONE 5th generation vs 4th generation troponin T in predicting outcomes in hospitalized patients
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symptoms included hypotension (9.1%), arrythmia (5.8%) or rhythm change (5.3%). There were
also 75 patients (8.2%) who reported non-cardiac symptoms at the time of troponin collection.
Table 1. Baseline demographics.
Frequency (N = 918) Percent
Age, yrs. 59.8 +/- 15.6 years
Male 506 55.1%
Female 412 44.9%
BMI 29.4 +/- 8.3
Tobacco
Never smoker 345 37.6%
Former smoker 223 24.3%
Current smoker 290 31.6%





Coronary Artery Disease 254 27.7%
Cerebrovascular Disease 224 24.4%
Chronic Kidney Disease 214 23.3%
Peripheral Artery Disease 58 6.3%
https://doi.org/10.1371/journal.pone.0246332.t001
Fig 1. Reason for index hospitalization.
https://doi.org/10.1371/journal.pone.0246332.g001
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No discrete symptoms were documented in over 43% of patients, most commonly as a part of a
routine order set for stroke patients in concordance with guideline documents [17].
ECGs were ordered in 93% of patients in whom a troponin was drawn. Over 50% of the
patients did not have any appreciable ECG abnormalities. Approximately 40% of patients had
non-specific ST/T wave abnormalities, and<10% had >1 mm ST depression or elevation on
their ECG.
Outcomes
Median peak 5th generation TnT values were 34 ng/L (IQR of 13–98 ng/L) while the median
peak 4th generation TnT values were 0.01 ng/mL (IQR of 0.01–0.071 ng/mL). Using the afore-
mentioned cutoffs for normal values, 69% (n = 635) of the study population had elevated 5th
generation TnT levels while 46% (n = 420) of the study population had elevated 4th generation
TnT levels. Correlation between the 5th generation and 4th generation TnT results focusing on
the lower levels are shown in S2 Fig.
The 5th generation TnT assay was more sensitive, but less specific for predicting ACM and
MACE than the 4th generation TnT assay. The sensitivities for the 5th generation TnT assay
were 85% for ACM and 90% for MACE rates, compared to 65% and 70% respectively for the
4th generation assay. The specificities for the 5th generation TnT assay were 45% for ACM and
35% for MACE rates, compared to 55% and 60% respectively for the 4th generation TnT assay
(S1 and S2 Tables). There was no difference in overall accuracy (Fig 2).
To classify, 286 patients were concordant negative (4th generation TnT -/5th generation
TnT -), 215 patients were discordant (4th generation TnT -/5th generation TnT +), and 420
patients were concordant positive (4th generation TnT +/5th generation TnT +). ACM and
MACE for the concordant negative was noted to be 11.1% and 1.0% respectively. Compared to
the concordant negative patients, the discordant patients had higher ACM rates at 27.5%
(p< 0.001) with no significant increase in MACE rates at 1.7% (p = 0.48). Finally, the concor-
dant positive patients had the highest rates of ACM at 42.1% (p< 0.001) and MACE rates at
5.9% (p< 0.0001) (Fig 3). MACE rates were distributed amongst all the different reasons for
admission with no statistically significant difference between the different categories (S3 Fig).
Table 2. Symptoms/indications for troponin and ECG findings.
Symptoms triggering ordering of troponin
Shortness of air 163 17.8%
Chest Pain 162 17.6%
Hypotension 83 9.0%
Arrythmia 53 5.8%
Rhythm Change 51 5.6%
Other 75 8.2%
No discrete symptoms documented 403 43.9%
Electrocardiogram Obtained 853 92.9%
Electrocardiogram Results
No ST deviation 374 43.8%
Non-Specific ST/T Wave Abnormality 333 39.0%
T-wave Inversion 14 1.6%
ST Elevation 13 1.5%
ST Depression 4 0.5%
Conduction Abnormality 159 18.6%
Other 173 20.3%
https://doi.org/10.1371/journal.pone.0246332.t002
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Discussion
The primary findings highlighted by this investigation include the following: 1) cardiovascular
risk is elevated compared to general populations, but not as high as amongst those with pri-
mary cardiovascular conditions reported in the literature; 2) 5th generation TnT assays are
more sensitive and identify a previously unidentified cohort of patients at risk for ACM but
not for MACE; and 3) cardiac troponin alone (either 4th generation or 5th generation TnT) are
likely not adequate as a diagnostic tool in isolation, but need to be integrated into a more com-
prehensive risk stratification schema.
The introduction of higher sensitivity troponin assays has largely focused on subgroups rou-
tinely assessed in the emergency department, either as those with suspected ACS or other non-dif-
ferentiated patients. However, troponin is routinely assessed in the hospitalized patients for
various reasons, including as a part of routine order sets, non-specific symptoms, or a decompen-
sating patient. In addition, there are more studies regularly that have emphasized cardiovascular
risk in these non-ACS hospitalized patients [10–12]. Understanding the connection (and therefore
the interpretation) between cardiac biomarkers and cardiovascular risk is essential in these hospi-
talized patients, especially given that>2/3rd of hospitalized patients in this cohort have elevated 5th
generation TnT values, an absolute increase in 20–25% compared to the 4th generation TnT.
Cardiovascular risk has recently been assessed broadly and with variable reported risk
amongst hospitalized patients [17–19]. This wide variation is often related to definitions and
methodology used. Coded data often overestimates the risk of cardiovascular events, and often
will yield complication rates as high as 25% at 1 year [20, 21]. Our study was extremely strin-
gent in outcome assessment, excluding all patients who were identified as having an ACS dur-
ing their initial presentation, adhering to the 4th Universal Definition of Myocardial Infarction
and requiring agreement between 2 cardiologists for cardiovascular outcomes [1]. With these
more stringent criteria, the MACE rate was higher at 1 year than a non-hospitalized cohort,
Fig 2. ROC curves for 4th generation troponin T and 5th generation troponin T for all-cause mortality (A) and MACE (B). ROC curves for both
troponin assays with no significant difference in the areas under the curve (AUC) both for all-cause mortality and MACE (p values>0.05).
https://doi.org/10.1371/journal.pone.0246332.g002
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but significantly lower than some previous reported cohorts [6–8, 11, 13, 14, 19, 20]. Accu-
rately identifying cardiac risk is essential, as it not only influences pre-test probability for sub-
sequent patients, but also influences over-interpretation of diagnostic testing that was never
studied for this clinical scenario. Given the rates of positive cardiac troponins, a better under-
standing of cardiovascular risk and the interpretation of troponin is essential to minimizing
inappropriate downstream testing and procedures.
The transition from the 4th generation TnT to the 5th generation TnT has led to an increase in
sensitivity at the expense of specificity for both ACM and MACE at 1 year. While not surprising,
this shift allows for 2 primary clinical benefits. First, the sensitivity/specificity profile of the 4th
generation TnT is difficult to apply clinically, while the improved sensitivity of the 5th generation
TnT, one may be considerably less concerned about future MACE in the biomarker negative
patient. The decreased specificity does not help in the interpretation of a positive 5th generation
TnT (which represents a majority of the patients), but it makes at least one potential result
actionable given the improved sensitivity. Second, the 5th generation TnT identifies a cohort of
patients at risk for ACM that was previously missed. Amongst those that were 5th generation
TnT positive and 4th generation TnT negative (the previously missed cohort), mortality rate was
~25–30% at 1 year, which is lower than the concordantly positive patients, but higher than the
concordantly negative patients. This relationship does not hold for identification of MACE.
While improving the overall sensitivity, the rates of MACE in the discordant troponin patients
were similar to concordantly negative troponin patients, and significantly less than the concor-
dantly positive troponin patients. Given lower than expected MACE and higher sensitivity, the
role of the 5th generation TnT is largely in ruling out those at risk for MACE, but of limited value
Fig 3. All-cause mortality and MACE rates based stratified based on 4th generation troponin T and 5th generation troponin T status. �P-value<0.05
compared to 4th generation—/ 5th generation–for all-cause mortality. &P-value<0.05 compared to 4th generation—/ 5th generation–for MACE.
https://doi.org/10.1371/journal.pone.0246332.g003
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in the positive test in isolation. Furthermore, the 5th generation TnT may be of added prognostic
value for predicting ACM, similar to previous studies, more so than the 4th generation TnT.
However, the limitation in specificity with the 5th generation TnT affects the overall area
under a receiver operator curve, making it comparable to the 4th generation in overall accu-
racy. For both assays, troponin interpretation in isolation is limited in the hospitalized, non-
ACS patient population. Previous studies have tried to assess for acute myocardial injury ver-
sus acute myocardial infarction in non-ACS presentations, but often were primarily in ED
patients that included primary admissions for heart failure and arrhythmias and included a
more liberal diagnostic criteria for outcomes (usually ICD codes). In addition to overestimat-
ing disease burden, there may also be added issues with introducing bias by identifying a more
heterogeneous cohort of both primary cardiac and non-cardiac patients. Given the lower than
expected MACE rates, subgroup analysis looking at different classifications would be intrinsi-
cally underpowered. This suggests the need for additional strategies for the assessment of car-
diovascular risk in hospitalized patients. Ongoing research should help to provide some
guidance, whether it be different cutoffs for cardiac troponin, other biomarkers or imaging
modalities to help identify a subgroup at risk for MACE [18, 22–27].
Conclusions
All-cause mortality and cardiovascular risk are elevated in patients hospitalized for non-cardiac
presentations compared to the general population. 5th generation TnT is more sensitive, and
less specific in predicting both ACM and MACE with limited overall accuracy for predicting
both outcomes. However, the 5th generation TnT appears to have an incremental value in iden-
tifying an intermediate risk group for all-cause mortality that was previously missed with the 4th
generation TnT assay. The 5th generation TnT should be leveraged as another marker of end-
organ involvement from a systemic illness, and not necessarily equivalent to or an adequate pre-
dictor of major adverse cardiovascular events in isolation. Additional tools need to be identified
to use with clinical risk factors and cardiac biomarkers to identify those truly at risk for MACE.
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